KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Current Assets (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Current Assets for 16 consecutive years, with $11.5 billion as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Current Assets fell 6.25% year-over-year to $11.5 billion, compared with a TTM value of $11.5 billion through Mar 2025, down 6.25%, and an annual FY2024 reading of $12.6 billion, up 0.54% over the prior year.
  • Current Assets was $11.5 billion for Q1 2025 at Teva Pharmaceutical Industries, down from $12.6 billion in the prior quarter.
  • Across five years, Current Assets topped out at $12.8 billion in Q2 2021 and bottomed at $11.4 billion in Q3 2023.
  • Average Current Assets over 5 years is $12.1 billion, with a median of $12.2 billion recorded in 2021.
  • The sharpest move saw Current Assets dropped 7.63% in 2023, then grew 6.92% in 2024.
  • Year by year, Current Assets stood at $12.6 billion in 2021, then fell by 4.15% to $12.1 billion in 2022, then increased by 3.6% to $12.5 billion in 2023, then rose by 0.54% to $12.6 billion in 2024, then decreased by 8.16% to $11.5 billion in 2025.
  • Business Quant data shows Current Assets for TEVA at $11.5 billion in Q1 2025, $12.6 billion in Q4 2024, and $11.6 billion in Q2 2024.